Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

NCT05006794 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Malignancies

Interventions

DRUG: zamzetoclax
DRUG: Docetaxel
DRUG: sacituzumab govitecan-hziy

Sponsor

Gilead Sciences